Validation of the Semiquantitative Static SUVR Method for 18F-AV45 PET by Pharmacokinetic Modeling with an Arterial Input Function
暂无分享,去创建一个
Steven Staelens | Sigrid Stroobants | Jeroen Verhaeghe | Hanne Struyfs | Jan Versijpt | Steven Deleye | Sebastiaan Engelborghs | Ellis Niemantsverdriet | H. Struyfs | S. Engelborghs | S. Stroobants | J. Versijpt | S. Staelens | S. Deleye | S. Ceyssens | J. Verhaeghe | F. Soetewey | J. Ottoy | L. Wyffels | Leonie Wyffels | Ellen De Roeck | S. Van Mossevelde | E. D. De Roeck | Julie Ottoy | Tobi Van den Bossche | E. Niemantsverdriet | Sara Van Mossevelde | Sarah Ceyssens | Charisse Somers | Femke Soetewey | T. Van den Bossche | Charisse Somers
[1] Rik Ossenkoppele,et al. Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic Considerations , 2013, The Journal of Nuclear Medicine.
[2] Simon A. Moss,et al. b -amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease , 2007 .
[3] S. DeKosky,et al. Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[4] Lars Farde,et al. Quantification of Blood Flow-Dependent Component in Estimates of Beta-Amyloid Load Obtained Using Quasi-Steady-State Standardized Uptake Value Ratio , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[5] S. Engelborghs,et al. Overdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up. , 2015, Journal of Alzheimer's disease : JAD.
[6] John Seibyl,et al. Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction , 2015, NeuroImage.
[7] H. Zetterberg,et al. Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia , 2015, Alzheimer's & dementia.
[8] Robert B. Innis,et al. Strategies to Improve Neuroreceptor Parameter Estimation by Linear Regression Analysis , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[9] J. Arrazola,et al. Amyloid PET imaging in multiple sclerosis: an 18F-florbetaben study , 2015, BMC Neurology.
[10] S. Shokouhi,et al. Reference tissue normalization in longitudinal 18F-florbetapir positron emission tomography of late mild cognitive impairment , 2016, Alzheimer's Research & Therapy.
[11] Oscar L Lopez,et al. Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET , 2015, The Journal of Nuclear Medicine.
[12] Salvatore Mazza,et al. Primary cerebral blood flow deficiency and Alzheimer's disease: shadows and lights. , 2011, Journal of Alzheimer's disease : JAD.
[13] R. Vandenberghe,et al. The interest of amyloid PET imaging in the diagnosis of Alzheimer's disease. , 2013, Current opinion in neurology.
[14] W. Jagust,et al. The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015 , 2015, Alzheimer's & Dementia.
[15] Masanori Ichise,et al. PET Quantification of 18F-Florbetaben Binding to β-Amyloid Deposits in Human Brains , 2013, The Journal of Nuclear Medicine.
[16] Karl Herholz,et al. Clinical amyloid imaging in Alzheimer's disease , 2011, The Lancet Neurology.
[17] James Robert Brašić,et al. In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.
[18] Vikash K. Sinha,et al. Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor , 2016, Alzheimer's & dementia.
[19] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[20] Sterling C. Johnson,et al. Effects of hypoperfusion in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.
[21] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[22] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[23] Daniel Bandy,et al. Improved Power for Characterizing Longitudinal Amyloid-β PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region , 2015, The Journal of Nuclear Medicine.
[24] C. Cobelli,et al. Evaluation of compartmental and spectral analysis models of [/sup 18/F]FDG kinetics for heart and brain studies with PET , 1998, IEEE Transactions on Biomedical Engineering.
[25] William J. Jagust,et al. Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios , 2015, The Journal of Nuclear Medicine.
[26] Tyler E. Benedum,et al. Preclinical Properties of 18F-AV-45: A PET Agent for Aβ Plaques in the Brain , 2009, Journal of Nuclear Medicine.
[27] T. Yen,et al. GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain. , 2010, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.